Because no standard approaches exist for patients with EGFR-mutated non–small cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next step in the treatment journey, Rami Manochakian, MD.
“This is a very hot topic now. There are some potential rare, resistant mechanisms that could be a secondary actionable mutation such as MET amplification where you can potentially give patients another targeted therapy,” Manochakian explained. “For some other promising resistance mutations, you can enroll patients on trials, whether you have them at your institution or elsewhere. Definitely, for any patient of mine who progresses on osimertinib, I do recommend repeat genomic testing.”
In an interview with OncLive® during the Institutional Perspectives in Cancer webinar on Lung Cancer, Manochakian, a thoracic medical oncologist at the Mayo Clinic, discussed the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation TKI, and ongoing research efforts to further improve care. Read more.